Musings on Markets • 0 implied HN points • 10 Nov 15
- The healthcare business has changed significantly over the past 25 years, especially with pharmaceuticals losing pricing power due to factors like more insurance consolidation and government negotiations.
- Biotechnology companies are growing rapidly and driving much of the revenue in the drug industry, while traditional pharmaceutical companies are facing stagnation.
- Investors are now more cautious about R&D spending in pharmaceuticals, focusing on results rather than just the amount spent, leading to a shift in how drug companies strategize for growth.